SCHEMBL860219

SCHEMBL860219

Oc1nnnn1-c1cccc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.50
HSD17B10 Q99714 2/20 0.50
ADRB2 P07550 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
HPGD P15428 4/20 0.48
MAPT P10636 3/20 0.48
NOTUM Q6P988 1/20 0.45
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
HTT P42858 3/20 0.44
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
NPC1 O15118 2/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 2/20 0.42
GLA P06280 1/20 0.42
PKM P14618 1/20 0.42
RAB9A P51151 1/20 0.42
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15104652 0.79 ALDH1A1 (0.49) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL10466989 0.79 ALDH1A1 (0.49) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL30353932 0.79 ALDH1A1 (0.49) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL859433 0.79 ALDH1A1 (0.49) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL10629073 0.77 ALDH1A1 (0.64) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL5551521 0.76 ALDH1A1 (0.46) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL11872333 0.72 ALDH1A1 (0.64) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL1493532 0.72 HSD11B1 (0.54) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL1702686 0.71 HSD11B1 (0.50) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD
SCHEMBL13547674 0.71 HSD11B1 (0.53) ALDH1A1HSD17B10ADRB2SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-17 US disclosed
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-17 US disclosed
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-17 US disclosed
EP-2432774-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS Ardea Biosciences, Inc. (US) 2012-03-28 EP disclosed
EP-2432468-A2 METHODS OF MODULATING URIC ACID LEVELS Ardea Biosciences, Inc. (US) 2012-03-28 EP disclosed
WO-2010135536-A2 METHODS OF MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed
WO-2010135536-A2 METHODS OF MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed
WO-2010135530-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed
WO-2010135530-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels XDH, PON1, RBP4 ALDH1A1 188/4885HSD17B10 1242/4885ADRB2 2982/4885
US-20120135929-A1 Methods Of Modulating Uric Acid Levels XDH, PON1, OAT ALDH1A1 167/4885HSD17B10 1635/4885ADRB2 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.